文献类型：期刊文献

英文题名：Primary small cell neuroendocrine carcinoma of the urinary tract: a case report and literature review

作者：Li X.; Chen B.; Li F.; Wang X.; Zhang X.; Zhao Y.; Zhang M.; Li H.

机构：[1]Department of Urology, Gansu Provincial Hospital, Lanzhou, 730000, China;[2]Gansu University of Chinese Medicine, Lanzhou, 730000, China

第一机构：Department of Urology, Gansu Provincial Hospital, Lanzhou, 730000, China

通信机构：[1]Department of Urology, Gansu Provincial Hospital, Lanzhou, 730000, China

年份：2026

卷号：24

期号：1.0

外文期刊名：World Journal of Surgical Oncology

收录：Scopus(收录号：2-s2.0-105027992135)

语种：英文

外文关键词：Clinicopathological features; Immunohistochemistry; Small cell neuroendocrine carcinoma; Tumor of the urinary tract

摘要：Background: Small cell neuroendocrine carcinoma of the urinary tract (SCC-UT) is an extremely rare genitourinary tumor, which is highly aggressive, prone to local or distant metastasis and has a very poor prognosis. Case presentation: This article reports a case of primary small cell neuroendocrine carcinoma of the ureter combined with invasive uroepithelial carcinoma. The patient underwent robot-assisted laparoscopic radical left nephrectomy, full-length ureteral resection, sleeve cystectomy, and pelvic lymph node dissection after exclusion of contraindications to surgery (preoperative assessment confirmed the absence of cardiopulmonary or coagulation abnormalities) and underwent 6 cycles of post operative etoposide/cisplatin adjuvant chemotherapy. Conclusions: This case underscores the potential efficacy of multimodal therapy, combining robot-assisted surgical resection with adjuvant etoposide/cisplatin chemotherapy, in the management of primary small cell neuroendocrine carcinoma. The patient was detected no local or distant metastases, at 9 months postoperatively. However, the follow-up period of only 9 months is relatively short, which limits the long-term assessment of recurrence or survival. These findings provide a reference for clinical decision-making and underscore the potential benefits of multimodal treatment in this rare malignancy. ? The Author(s) 2025.